Ubiquitin ligase kpc1 promotes processing of p105 nf-kappab1 to p50, eliciting strong tumor suppression

Abstract

The invention provides a method for treating cancer comprising the step of administering a therapeutically effective amount of KPC1, a peptide which is at least about 70% homologous to the KPC1 or an agent which up-regulates KPC1. In some embodiments, there is also provided a method for treating cancer comprising the step of administering a therapeutically effective amount of p50, a peptide which is at least about 70% homologous to the p50 or an agent which up-regulates p50.

What is claimed is: 
     
         1 . A method of treating cancer in a subject comprising the step of administering to said subject a therapeutically effective amount of a peptide comprising p50, peptide which is at least about 70% homologous to the p50 sequence as set forth in SEQ ID NO: 3 or an agent which upregulates p50; a fused protein comprising p50 or the peptide which is at least about 70% homologous to the p50 sequence as set forth in SEQ ID NO: 3 or the agent which up-regulates p50; or a complex comprising p50, the peptide which is at least about 70% homologous to the p50 sequence as set forth in SEQ ID NO: 3 or the agent which upregulates p50 or the fused protein that comprises p50, the peptide which is at least about 70% homologous to the p50 sequence as set forth in SEQ ID NO: 3 or the agent which upregulates p50, to a subject in need, thereby treating cancer. 
     
     
         2 . The method of any one of  claim 1 , wherein the cancer is breast cancer, bone osteosarcoma or glioblastoma.